Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy
- Supplementary File 1:
ZIP-Document (ZIP, 13949 KiB)
Kim, B.-H.; Lee, H.; Song, Y.; Park, J.-S.; Gadhe, C.G.; Choi, J.; Lee, C.-G.; Pae, A.N.; Kim, S.; Ye, S.-K. Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy. J. Clin. Med. 2019, 8, 1847. https://doi.org/10.3390/jcm8111847
Kim B-H, Lee H, Song Y, Park J-S, Gadhe CG, Choi J, Lee C-G, Pae AN, Kim S, Ye S-K. Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy. Journal of Clinical Medicine. 2019; 8(11):1847. https://doi.org/10.3390/jcm8111847
Chicago/Turabian StyleKim, Byung-Hak, Haeri Lee, Yeonghun Song, Joon-Suk Park, Changdev G. Gadhe, Jiwon Choi, Chung-Gi Lee, Ae N. Pae, Sanghee Kim, and Sang-Kyu Ye. 2019. "Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy" Journal of Clinical Medicine 8, no. 11: 1847. https://doi.org/10.3390/jcm8111847